Voluntary announcement update on the strategic expansion of large-scale peptide CDMO production capacity
Filed with HKEX · Stock code 3880 · · 2 pages · English
Medtide Medtide Inc. VOLUNTARY ANNOUNCEMENT UPDATE ON THE STRATEGIC EXPANSION OF LARGE-SCALE PEPTIDE CDMO PRODUCTION CAPACITY This announcement is made by Medtide Inc. (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis to provide the shareholders and potential investors of the Company with information on the latest business development and progress of the production
Earlier from Medtide
- List of directors and their roles and functions
- Resignation of executive director
- Notification Letter and Reply Form to Non-registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications
- 2026 Interim report
- CPC Scientific Announces U.S. FDA Pre-License Inspection (PLI) Successfully Completed at Its Hangzhou cGMP Manufacturing Facility for Hepcludex® API, Establishing a Proven Track Record Under the Stringent BLA Pathway
Later from Medtide
All Medtide news releasesFollow Medtide into a list and get an email when it puts out news.
Follow Medtide